



CORRECTIVE STATEMENT

CORRECTIVE STATEMENT ON THE CONSOLIDATED FINANCIAL STATEMENTS AS OF 31 DECEMBER 2023

Paris, May 17 2024, 6pm CET

AB Science SA (Euronext - FR0010557264 - AB) communicates a corrective statement on the consolidated accounts as of December 31, 2023.

The inversion of an accounting entry in the valuation of financial instruments has generated an error in the consolidated financial results. This accounting entry has no impact on the parent company financial statements and no impact on the company's financial position.

The 2023 annual financial report is available on the Company's website.

CONSOLIDATED FINANCIAL INFORMATION FOR THE YEAR 2023

The operating result as of 31 December 2023 was a loss of €13,429k, compared with a loss of €15,937k as of 31 December 2022, a decrease in the operating loss of €2,508k (15.7%).

- Operating income, exclusively made up of revenues related to the operation of a drug in veterinary medicine, amounted to €970k as of 31 December 2023, compared to €958k a year earlier.
- Operating expenses decreased by 14.8% between the years ended 31 December 2023 and 2022. This decrease is mainly due to lower research and development costs (down 21.5%).
- Marketing expenses were stable compared to 31 December 2022, rising from €480k as of 31 December 2022 to €522k as of 31 December 2023.
- Administrative expenses were stable compared to 31 December 2022, decreasing from €3,040k as of 31 December 2022 to €3,017k as of 31 December 2023.
- Research and development costs decreased by €2,868k, or 21.5%, from €13,345k as of 31 December 2022 to €10,477k as of 31 December 2023.

Net financial income for the years ended 31 December 2022 and 31 December 2023 was €2,326k and €1,444k respectively. In 2023, as in 2022, this financial result has no cash impact. The financial result of €1,444k includes income of €3,320k (versus €3,167k in 2022) resulting from the valuation of these financial instruments, and a financial expense of €2,521k (versus €948k in 2022), of which €941k corresponds to the provision for capitalised interest relating to the loan with the EIB.

The consolidated net loss as of 31 December 2023 is €11,985k compared to a loss of €13,615k as of 31 December 2022, a decrease of 12%.

The following tables summarize the consolidated financial statements for the year 2023 prepared in accordance with IFRS, and the correction made.

Consolidated results after correction :

<i>In thousands of euros, except for share data</i>	31/12/2023	31/12/2022
Net turnover	970	958
Cost of sales	(383)	(31)
Marketing expenses	(522)	(480)
Administrative expenses	(3,017)	(3,040)
Research and development expenses	(10,477)	(13,345)
Operating income	(13,429)	(15,937)
Financial income	4,993	4,904
Financier expenses	(3,549)	(2,578)
Financial income	1,444	2,326
Net income	(11,985)	(13,615)
Total comprehensive income for the period	(11,729)	(13,356)
Basic earnings per share - in euros	(0,24)	(0,29)
Diluted earnings per share - in euros	(0,24)	(0,29)

Correction made :

<i>In thousands of euros, except for share data</i>	31/12/2023	31/12/2022
Net turnover	970	958
Cost of sales	(383)	(31)
Marketing expenses	(522)	(480)
Administrative expenses	(3,017)	(3,040)
Research and development expenses	(10,477)	(13,345)
Operating income	(13,429)	(15,937)
Financial income	4,993 5,962	4,904
Financier expenses	(3,549) (2,580)	(2,578)
Financial income	1,444 3,382	2,326
Net income	(11,985) (10,048)	(13,615)
Total comprehensive income for the period	(11,729) (9,791)	(13,356)
Basic earnings per share - in euros	(0,24) (0,20)	(0,29)
Diluted earnings per share - in euros	(0,24) (0,20)	(0,29)

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website:

www.ab-science.com.

Forward-looking Statements - AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development

of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science

Financial Communication & Media Relations

investors@ab-science.com